Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 30052C107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Soleus Capital Master Fund, L.P.
13G
|
5.3% |
8/31/2026
Event 8/27/2026
|
|
| Soleus Capital Master Fund, L.P. | 5.3% | ||
| Soleus Capital, LLC | 5.3% | ||
| Soleus Capital Group, LLC | 5.3% | ||
| Soleus Capital Management, L.P. | 5.3% | ||
| Soleus GP, LLC | 5.3% | ||
| Guy Levy | 5.3% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/26/2026
Event 3/13/2026
|
|
|
Caligan Partners LP
13G/A
Amendment 2
|
0% |
2/17/2026
Event 12/31/2025
|
|
| Caligan Partners LP | 0% | ||
| David Johnson | 0% | ||
|
Tang Capital Management LLC
13G/A
Amendment 4
|
1.9% |
2/17/2026
Event 12/31/2025
|
|
| Tang Capital Management, LLC | 1.9% | ||
| Kevin Tang | 1.9% | ||
| Tang Capital Partners, LP | 1.0% | ||
| Tang Capital Partners International, LP | 0.8% | ||
| Tang Capital Partners III, Inc | 0.1% | ||
| Tang Capital Partners IV, Inc | <0.1% | ||
| Timothy P. Lynch 13G/A Amendment 2 | 9.9% |
2/17/2026
Event 12/31/2025
|
|
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
8.9% |
11/14/2025
Event 9/30/2025
|
|
| Nantahala Capital Management, LLC | 8.9% | ||
| Wilmot B. Harkey | 8.9% | ||
| Daniel Mack | 8.9% | ||
| Timothy P. Lynch 13G/A Amendment 1 | 7.9% |
11/14/2025
Event 9/30/2025
|
|
|
Caligan Partners LP
13G/A
Amendment 1
|
6.4% |
11/14/2025
Event 9/30/2025
|
|
| Caligan Partners LP | 6.4% | ||
| David Johnson | 6.4% | ||
| Timothy P. Lynch 13G | 6.3% |
8/18/2025
Event 8/11/2025
|
|
|
Perceptive Advisors LLC
13G/A
Amendment 4
|
3.8% |
8/14/2025
Event 6/30/2025
|
|
| Perceptive Advisors LLC | 3.8% | ||
| Joseph Edelman | 3.8% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 3.8% | ||
|
Caligan Partners LP
13G
|
5.2% |
8/14/2025
Event 6/30/2025
|
|
| Caligan Partners LP | 5.2% | ||
| David Johnson | 5.2% | ||
|
Tang Capital Management LLC
13G/A
Amendment 3
|
7.9% |
5/15/2025
Event 3/31/2025
|
|
| Tang Capital Management, LLC | 7.9% | ||
| Kevin Tang | 7.9% | ||
| Tang Capital Partners, LP | 5.5% | ||
| Tang Capital Partners International, LP | 1.3% | ||
| Tang Capital Partners III, Inc | 1.0% | ||
| Tang Capital Partners IV, Inc | 0.1% | ||
|
Nantahala Capital Management, LLC
13G
|
5.9% |
5/15/2025
Event 3/31/2025
|
|
| Nantahala Capital Management, LLC | 5.9% | ||
| Wilmot B. Harkey | 5.9% | ||
| Daniel Mack | 5.9% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 3
|
6.4% |
5/15/2025
Event 3/31/2025
|
|
| Perceptive Advisors LLC | 6.4% | ||
| Joseph Edelman | 6.4% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 6.4% | ||
| Medytox Inc. 13G/A Amendment 4 | 3.4% |
2/6/2025
Event 12/31/2024
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 6.9% |
2/5/2025
Event 12/31/2024
|
|
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
4.5% |
11/14/2024
Event 9/30/2024
|
|
| Nantahala Capital Management, LLC | 4.5% | ||
| Wilmot B. Harkey | 4.5% | ||
| Daniel Mack | 4.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 4.52 k | $36.1 k |
| 2026 Q2 | 172 | 55.5 M | $385 M |
| 2026 Q1 | 156 | 45.7 M | $188 M |
| 2025 Q4 | 176 | 49.2 M | $327 M |
| 2025 Q3 | 169 | 54.9 M | $337 M |
| 2025 Q2 | 185 | 59.6 M | $548 M |
| 2025 Q1 | 188 | 54.3 M | $653 M |
| 2024 Q4 | 169 | 51.9 M | $573 M |
| 2024 Q3 | 172 | 50.5 M | $817 M |
| 2024 Q2 | 170 | 56.8 M | $616 M |
| 2024 Q1 | 179 | 56.5 M | $791 M |
| 2023 Q4 | 163 | 51.2 M | $539 M |
| 2023 Q3 | 147 | 41.5 M | $379 M |
| 2023 Q2 | 143 | 37.3 M | $271 M |
| 2023 Q1 | 134 | 35.1 M | $297 M |
| 2022 Q4 | 129 | 30.8 M | $231 M |
| 2022 Q3 | 136 | 26.3 M | $212 M |
| 2022 Q2 | 130 | 26.1 M | $303 M |
| 2022 Q1 | 126 | 24.7 M | $275 M |
| 2021 Q4 | 119 | 20.8 M | $134 M |
| 2021 Q3 | 126 | 17.6 M | $135 M |
| 2021 Q2 | 126 | 16.2 M | $205 M |
| 2021 Q1 | 106 | 8.61 M | $112 M |
| 2020 Q4 | 107 | 9.46 M | $31.8 M |
| 2020 Q3 | 104 | 7.30 M | $28.8 M |
| 2020 Q2 | 111 | 9.29 M | $49.2 M |
| 2020 Q1 | 120 | 14.3 M | $59.0 M |
| 2019 Q4 | 125 | 14.3 M | $174 M |
| 2019 Q3 | 107 | 5.66 M | $88.5 M |
| 2019 Q2 | 128 | 5.48 M | $80.1 M |
| 2019 Q1 | 109 | 3.95 M | $89.3 M |
| 2018 Q4 | 82 | 5.53 M | $65.8 M |
| 2018 Q3 | 75 | 6.94 M | $129 M |
| 2018 Q2 | 57 | 3.53 M | $98.8 M |
| 2018 Q1 | 42 | 4.45 M | $40.2 M |
| 2016 Q1 | 1 | 12.8 k | $286 k |